Penumbra (PEN) Share-based Compensation (2014 - 2026)
Penumbra's (PEN) quarterly Share-based Compensation came in at $14.6 million in Q1 2026, up 1647.61% year-on-year from $838000.0 in Q1 2025, and up 135.37% on a QoQ basis from -$41.4 million in Q4 2025.
Penumbra (PEN) Share-based Compensation (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Share-based Compensation data on file, last reported at $14.6 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 1647.61% year-over-year to $14.6 million in Q1 2026; TTM through Mar 2026 was $16.4 million, a 482.99% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 6.62% from the prior year.
- Share-based Compensation for Q1 2026 stood at $14.6 million, up from -$41.4 million in the prior quarter.
- Over the last five years, Share-based Compensation for PEN reached as high as $49.4 million in Q4 2023 and fell as low as -$43.5 million in Q4 2022.
- Historically, Share-based Compensation has averaged $4.6 million across 5 years, with a median of $838000.0 in 2025.
- On a YoY basis, Share-based Compensation climbed as much as 559416.67% in 2024 and fell as far as 164.17% in 2024.
- Year by year, Share-based Compensation stood at -$43.5 million in 2022, then soared by 213.61% to $49.4 million in 2023, then slumped by 164.17% to -$31.7 million in 2024, then tumbled by 30.69% to -$41.4 million in 2025, then jumped by 135.37% to $14.6 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $14.6 million in Q1 2026, -$41.4 million in Q4 2025, and $41.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.44 Bn | 175.14 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 128.91 Bn | 126.03 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 68.45 Bn | 67.00 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 47.59 Bn | 43.92 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 28.59 Bn | 27.48 Bn | 750.30 Mn | 35.80 Mn |
| 7 | GE HealthCare Technologies | 28.53 Bn | 26.24 Bn | 1.98 Bn | 35.00 Mn |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.42 Bn | 22.30 Bn | 2.07 Bn | 35.12 Mn |
| 10 | Penumbra | 12.56 Bn | 11.95 Bn | 253.41 Mn | 14.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.65 Mn |
| Mar 31, 2026 | 14.65 Mn |
| Dec 31, 2025 | -41.41 Mn |
| Dec 31, 2025 | -41.41 Mn |
| Sep 30, 2025 | 41.14 Mn |
| Sep 30, 2025 | 41.14 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 838,000.00 |
| Mar 31, 2025 | 838,000.00 |
| Dec 31, 2024 | -31.68 Mn |
| Dec 31, 2024 | -31.68 Mn |
| Sep 30, 2024 | 33.56 Mn |
| Sep 30, 2024 | 33.56 Mn |
| Jun 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 89,000.00 |
| Mar 31, 2024 | 421,000.00 |
| Mar 31, 2024 | 421,000.00 |
| Dec 31, 2023 | 49.37 Mn |
| Dec 31, 2023 | 49.37 Mn |